drugset
drugset / Trial / NCT04142749

Oltipraz for Liver Fat Reduction in Patients With Non-alcoholic Fatty Liver Disease Except for Liver Cirrhosis

NCT04142749 ↗

Phase 3 Completed 146 enrolled PharmaKing
RandomizedParallel-groupSingle-blindTreatment

Summary

Oltipraz inhibits fatty acid synthesis through AMPK-S6K1 pathway and LXRg-SREBP-1c pathway in liver.

Timeline

Start
2019-11-15
Primary completion
2022-09-02
Completion
2022-09-26

Drugs

EvaluationDrugModalityDoseRoute
Comparator Oltipraz Small molecule 30 mg Oral

Indications

NAFLD1